Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 10:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 31 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Pfizer-BioNTech COVID-19 Vaccine Clear all
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines

NCT04889209
View directory record Official record
Conditions
COVID-19
Interventions
Ad26.COV2.S, BNT162b2, mRNA-1273, mRNA-1273.211, mRNA-1273.222, SARS-CoV-2 rS/M1
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
867 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
10
States / cities
Decatur, Georgia • Baltimore, Maryland • New York, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2025 · Synced Sep 26, 2026, 10:02 AM EDT
Recruiting No phase listed Observational

COVID-19 Vaccines Safety Tracking (CoVaST)

NCT04834869
View directory record Official record
Conditions
Adverse Reaction to Vaccine, COVID19 Vaccine
Interventions
BNT162b2, mRNA-1273, AZD1222, CoronaVac, Sinopharm, Gam-COVID-Vac, JNJ-78436735, CVnCoV, NVX-CoV2373, BBV152
Biological
Lead sponsor
Masaryk University
Other
Eligibility
18 Years and older
Enrollment
30,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Sep 26, 2026, 10:02 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.

NCT06178991
View directory record Official record
Conditions
Influenza, COVID-19
Interventions
Influenza and COVID-19 Combination A, Licensed influenza vaccine, COVID-19 Vaccine, Influenza and COVID-19 Combination B, Placebo, Investigational influenza vaccine
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years to 64 Years
Enrollment
8,795 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
106
States / cities
Athens, Alabama • Birmingham, Alabama • Mobile, Alabama + 76 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Sep 26, 2026, 10:02 AM EDT
Completed No phase listed Observational

Pfizer-BioNTech COVID-19 Vaccine Effectiveness Study - Kaiser Permanente Southern California

NCT04848584
View directory record Official record
Conditions
COVID-19
Interventions
Primary Exposure Status of Pfizer-BioNTech COVID-19 Vaccine, BNT162b2 BA.4/5 bivalent, XBB.1.5-adapted vaccinated
Biological
Lead sponsor
Pfizer
Industry
Eligibility
0 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Sep 26, 2026, 10:02 AM EDT
Active, not recruiting No phase listed Observational

A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza

NCT05160636
View directory record Official record
Conditions
COVID-19, Coronavirus Disease 2019, Influenza
Interventions
COVID-19 Vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 26, 2026, 10:02 AM EDT
Terminated No phase listed Observational

Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data

NCT05876377
View directory record Official record
Conditions
SARS-CoV-2, COVID-19, Post-Acute COVID-19 Syndrome
Interventions
Pfizer-BioNTech COVID-19 mRNA vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
6 Months and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 26, 2026, 10:02 AM EDT
Completed Phase 2 Interventional Results available

COVID Protection After Transplant - Sanofi GSK (CPAT-SG) Study

NCT05518487
View directory record Official record
Conditions
COVID-19, Kidney Transplant
Interventions
Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
San Diego, California • San Francisco, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Sep 26, 2026, 10:02 AM EDT
Terminated Phase 2 Interventional Results available

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

NCT05000216
View directory record Official record
Conditions
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
Interventions
Moderna mRNA-1273, BNT162b2, Ad26.COV2.S, Continue IS (MMF or MPA), Continue IS (MTX), Continue IS (B cell depletion therapy), Monovalent [B.1.351] CoV2 preS dTM-AS03, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, BNT162b2, Bivalent
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
29
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 26, 2026, 10:02 AM EDT
Terminated No phase listed Observational

Estimated Vaccine Effectiveness and Durability of Pfizer/BioNTech 2024-2025 COVID-19 Vaccine

NCT06703190
View directory record Official record
Conditions
COVID-19
Interventions
Pfizer-BioNTech BNT162b2 COVID-19 Vaccinated, Not vaccinated with 2024-2025 formulated COVID-19 vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
5 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Sep 26, 2026, 10:02 AM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers

PROSPECTIVE OPEN LABEL CLINICAL TRIAL TO ADMINISTER A BOOSTER DOSE OF PFIZER/BIONTECH OR MODERNA COVID-19 VACCINE IN HIGH-RISK INDIVIDUALS

NCT05279365
View directory record Official record
Conditions
SARS CoV 2 Infection, COVID-19
Interventions
Pfizer/BioNTech (BNT162b2), Moderna
Biological
Lead sponsor
DHR Health Institute for Research and Development
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
4
States / cities
Brownsville, Texas • Edinburg, Texas • Rio Grande City, Texas
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Sep 26, 2026, 10:02 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations

NCT04761822
View directory record Official record
Conditions
SARS-CoV Infection, COVID-19, Allergic Reaction, Mast Cell Disorder
Interventions
Moderna COVID-19 Vaccine, Pfizer-BioNTech COVID-19 Vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
5 Years and older
Enrollment
746 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
29
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Sep 26, 2026, 10:02 AM EDT
Not yet recruiting Phase 2 Interventional

Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant Patients

NCT07390968
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm
Interventions
SARS-CoV-2 mRNA Vaccine ARCT-021, Tozinameran, Biospecimen Collection, Electronic Health Record Review, Survey Administration
Biological · Procedure · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 26, 2026, 10:02 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

COVID-19 Vaccine Responses in PIDD Subjects

NCT05321407
View directory record Official record
Conditions
X-linked Agammaglobulinemia, XLA, Primary Immune Deficiency, CVID, Common Variable Immunodeficiency, Primary Antibody Deficiencies, Secondary Hypogammaglobulinemia
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
6 Months and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
3
States / cities
St. Petersburg, Florida • Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 2, 2025 · Synced Sep 26, 2026, 10:02 AM EDT
Completed No phase listed Observational Results available

COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States

NCT05020145
View directory record Official record
Conditions
Immunocompromised, Immunosuppressed, Covid-19, SARS-COV-2, SARS-COV-2 Infection, Breakthrough Infection
Interventions
BNT162b2 (Tozinameran)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
1,277,747 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 11, 2024 · Synced Sep 26, 2026, 10:02 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People

NCT06821061
View directory record Official record
Conditions
Influenza, COVID-19 (Coronavirus Disease 2019)
Interventions
Investigational Influenza Vaccine, Investigational COVID-19 Vaccine, Investigational Influenza and COVID-19 Combination Vaccine, Licensed Influenza Vaccine 1, Licensed Influenza Vaccine 2, Licensed Influenza Vaccine 3, Licensed COVID-19 Vaccine
Biological · Combination Product
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
2,650 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
31
States / cities
Anaheim, California • Lake Forest, California • Riverside, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 26, 2026, 10:02 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study

NCT07287137
View directory record Official record
Conditions
COVID -19, COVID - 19, COVID 19, Influenza, Respiratory Virus, Respiratory Viruses, Respiratory Virus Infection, Respiratory Virus Infections
Interventions
Pfizer-BioNTech mRNA COVID-19 vaccine, Novavax recombinant protein vaccine
Drug
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 79 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 26, 2026, 10:02 AM EDT
Completed Phase 2 Interventional Results available

The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose

NCT04977479
View directory record Official record
Conditions
Systemic Allergic Reaction
Interventions
Pfizer-BioNTech COVID-19 Vaccine (Comirnaty), Placebo, Pfizer-BioNTech COVID-19 Vaccine, Bivalent
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years to 69 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2023 · Synced Sep 26, 2026, 10:02 AM EDT
Completed Phase 2 Interventional Results available

COVID Protection After Transplant-Immunosuppression Reduction

NCT05077254
View directory record Official record
Conditions
Kidney Transplant Recipients, Liver Transplant Recipients
Interventions
Pfizer-BioNTech COVID-19 Vaccine 2023-2024, Moderna COVID-19 Vaccine 2023-2024, SOC IS Regimen, SOC IS Reduction
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
15
States / cities
San Diego, California • San Francisco, California • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 26, 2026, 10:02 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection

NCT06672055
View directory record Official record
Conditions
SARS-CoV2, COVID-19
Interventions
VXA-CoV2-3.1, COMIRNATY®, VXA-CoV2-3.3
Biological
Lead sponsor
Vaxart
Industry
Eligibility
18 Years and older
Enrollment
5,485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
145
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 126 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 26, 2026, 10:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Wearable Diagnostic for Detection of COVID-19 Infection

NCT04742569
View directory record Official record
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
ClinOne, Inc.
Industry
Eligibility
18 Years and older
Enrollment
790 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Greenwood Village, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Sep 26, 2026, 10:02 AM EDT
Completed No phase listed Observational Results available

This Study Intends to Describe the Characteristics of Patients Given the Pfizer-BioNTech Bivalent mRNA COVID-19 Vaccine and Any Commercially Available Influenza Vaccines at the Same Time Versus at Different Times.

NCT05858450
View directory record Official record
Conditions
Influenza, Human, COVID-19
Interventions
Comirnaty, Quadrivalent Influenza Vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
3,442,996 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Sep 26, 2026, 10:02 AM EDT
Completed Phase 4 Interventional Results available

Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction

NCT05212610
View directory record Official record
Conditions
COVID-19, Corona Virus Infection
Interventions
Pfizer-BioNTech mRNA COVID-19 vaccine, Moderna mRNA COVID-19 vaccine
Biological
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 26, 2026, 10:02 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine

NCT04952402
View directory record Official record
Conditions
Covid19, SARS-CoV2 Infection
Interventions
Study-provided Moderna mRNA-1273 COVID-19 vaccine, Community-provided Moderna mRNA-1273 COVID-19 Vaccine, Community-Provided Pfizer-BioNTech BNT162b2 COVID-19 Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
6
States / cities
Los Angeles, California • San Diego, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Sep 26, 2026, 10:02 AM EDT
Completed No phase listed Observational

Post COVID-19 Vaccination Analysis in Healthcare Worker Recipients

NCT04922944
View directory record Official record
Conditions
Covid19, Vaccine Reaction
Interventions
COVID-19 vaccine
Drug
Lead sponsor
Huntington Memorial Hospital
Other
Eligibility
Not listed
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 26, 2026, 10:02 AM EDT